

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

### Complete if Known

Application Number	10/551,997
Filing Date	October 4, 2005
First Named Inventor	Kai SCHIEMANN et al.
Group Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	MERCK-3071

### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Francois Giuliano et al., "The Pharmacological Treatment of Premature Ejaculation"; Journal Compilation, 2008; Vol. 102, pp. 668-675	
	2	Andrew W. Goddard et al., "Serotonergic Mechanisms in the Treatment of Obsessive-Compulsive Disorder"; Drug Discovery Today, April, 2008, Vol. 13, pp. 325-332.	
	3	Lucianne Groenink et al., "The Corticosterone-enhancing Effects of the 5-HT <sub>1A</sub> receptor antagonist...", European Journal of Pharmacology, Vol. 272, 1995, pp. 177-183.	
	4	Timo Heinrich et al., "Dual 5-HT <sub>1A</sub> agonists and 5-HT Re-uptake Inhibitors by Combination of...", Bioorganic & Medicinal Chemistry, Vol. 12, 2004, pp. 4843-4852.	
	5	5-HT <sub>1A</sub> Autoreceptors and the Mode of Action of Selective Serotonin Reuptake Inhibitors (SSRI), Behavioural Brain Research, Vol. 73, 1996, pp. 281-283.	
	6	Sean L. Kitson, "5-Hydroxytryptamine (5-HT) Receptor Ligands", Current Pharmaceutical Design, Vol. 13, 2007, pp. 2621-2637.	
	7	Helmi L. Lutsep, "Repinotan, A 5-HT <sub>1A</sub> Agonist, in the Treatment of Acute Ischemic Stroke", Current Drug Targets – CNS & Neurological Disorders, 2005, Vol. 4, pp. 119-120.	
	8	Lisa Matzen et al., "5-HT Reuptake Inhibitors With 5-HT Antagonistic Activity...", Journal of Medicinal Chemistry, 2000, Vol. 43 (6), pp. 1149-1157.	
	9	Gerd D. Bartoszyk et al., "EMD 281014, a New Selective Serotonin 5-HT <sub>2A</sub> Receptor Antagonist", European Journal of Pharmacology, Vol. 473, 2003, pp. 229-230.	
	10	Regis Bordet et al., "Effect of Pindolol on Onset of Action of Paroxetine...", Am J Psychiatry, 1998; Vol. 155, pp. 1346-1351.	
	11	Alan D. Brown et al., "Designing Drugs for the Treatment of Female Sexual Dysfunction", Drug Discovery Today, Sept. 2007, Vol. 12, pp. 757-766	
	12	Enza Lacivita et al., "5-HT <sub>1A</sub> , Receptor, an Old Target for New Therapeutic Agents », Current Topics in Medical Chemistry, 2008, Vol. 8, pp. 1024-1034.	
	13	Luisa de Angelis, "5-HT <sub>2A</sub> Antagonists in Psychiatric Disorders", Current Opinion in Investigational Drugs 2002, Vol. 3(1), pp. 106-112.	
	14	Giuseppe di Giovanni et al., "Serotonin Involvement in the Basal Ganglia Pathophysiology...", Current Medicinal Chemistry, 2006, Vol. 13, pp. 3069-3081.	
	15	Laura J. Dreshfield et al., "Enhancement of Fluoxetine-Dependent Increase of Extracellular...", Neurochemical Research, 1996, Vol. 21, No. 5, pp. 557-562.	
	16	Ray W. Fuller, "Uptake Inhibitors Increase Extracellular Serotonin Concentration Measured by Brain Microdialysis", Life Sciences, 1994, Vol. 55, No. 3, pp. 163-167.	
	17	Patricia W. Nance, "Alpha Adrenergic and Serotonergic Agents in the Treatment of Spastic Hygtonia", physical Medicine and Rehabilitation Clinics of North America, 2001, Vol. 12, No. 4, pp. 889-905.	
	18	Ian A. Pullar et al., "In Vitro Activity of LY393558, an Inhibitor of the 5-Hydroxytryptamine Transporter...", European Journal of Pharmacology, 2001, Vol. 432, pp. 9-17.	

	19	D.J. Sanger, "New Perspectives for the Treatment of Disorders of Sleep and Arousal", Ann Pharm Fr, 2007, Vol. 65, p. 268-274.	
	20	Kristine J. Steffen, "Emerging Drugs for Eating Disorder Treatment", Expert Opin, Emeerfing Drugs, 2006, Vol. 11, No. 2, pp. 315-336.	
	21	Raffaella Zanardi et al., "How Long Should Pindolol be Associated With Paroxetine...", Journal of Clinical Psychopharmacology, Vol. 17, No. 6, pp. 446-450.	
	22	"Serotonergic Mechanisms in Amyotrophic Lateral Sclerosis", intern. J. Neuroscience, 2006, Vol. 116, pp. 775-826.	
	23	L. Romero et al., "Two Actions are Better Than One: Avoding Self-Inhibititon...", International Clinical Psychopharmacology, 1996, Vol. 11, pp. 1-8.	

Examiner Signature		Date Considered
-----------------------	--	--------------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.